Stay updated with breaking news from Philippe Dubuc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing results in drastic decrease in peptide-drug conjugate
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft modelsSORT1 gene silencing results in drastic decrease in peptide-drug conjugate
MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today
Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers